25 assets in Urinary System Neoplasm

Therapeutic assets addressing Urinary System Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Normal Human Serum Albumin Urinary System Neoplasm	Region Skane	P4	BB (67)
Abemaciclib Urinary System Neoplasm	Eli Lilly and Company	P3	B (60)
Abiraterone Urinary System Neoplasm	Eli Lilly and Company	P3	B (60)
Fulvestrant Urinary System Neoplasm	Atavistik Bio, Inc	P2	B (60)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide Urinary System Neoplasm	Sichuan Baili Pharmaceutical Co., Ltd.	P2	B (60)
Pembrolizumab Urinary System Neoplasm	Sheba Medical Center	P2	B (60)
Prednisolone Urinary System Neoplasm	Eli Lilly and Company	P3	B (60)
Volitinib Urinary System Neoplasm	AstraZeneca	P3	B (60)
[18f]rccb6 Urinary System Neoplasm	RenJi Hospital	P2	CCC (53)
Ipilimumab Urinary System Neoplasm	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (53)
Lenvatinib Urinary System Neoplasm	Sheba Medical Center	P2	CCC (53)
Niraparib Urinary System Neoplasm	Xiaoxiang Chen	P2	CCC (53)
Nivolumab Urinary System Neoplasm	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (53)
NKT2152 Urinary System Neoplasm	NiKang Therapeutics, Inc.	P2	CCC (53)
Palbociclib Urinary System Neoplasm	NiKang Therapeutics, Inc.	P2	CCC (53)
Trastuzumab Urinary System Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Trastuzumab Emtansine Urinary System Neoplasm	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Tucatinib Urinary System Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Vipivotide Tetraxetan Urinary System Neoplasm	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (53)
Tyra-300 Urinary System Neoplasm	Tyra Biosciences, Inc	P1/2	CCC (48)
177Lu-rhPSMA-10.1 Urinary System Neoplasm	Blue Earth Therapeutics Ltd	P1/2	CC (47)
Star0602 Urinary System Neoplasm	Marengo Therapeutics, Inc.	P1/2	CC (47)
Atv-1601 Urinary System Neoplasm	Atavistik Bio, Inc	P1	CC (43)
Sasanlimab Urinary System Neoplasm	NiKang Therapeutics, Inc.	P2	C (34)
68Ga-HTK03149 Urinary System Neoplasm	British Columbia Cancer Agency	N/A	D (30)